基本情報
- 標準SMILES
Cc1cnc(C(=O)O)c[n+]1[O-]- InChIKey
DJQOOSBJCLSSEY-UHFFFAOYSA-N- 分子式
- C6H6N2O3
- 平均分子量
- 154.12 g/mol
- 単同位体質量
- 154.03784205
概要
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.
名称と識別子
- 優先名称
- Acipimox
- IUPAC
- 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
- 現地名
- アシピモックス
- 英語名
- Acipimox
- 分子式
- C6H6N2O3
- 分子量
- 154.12
名称と別名
名称をさらに表示
データベース識別子
- CAS
51037-30-0- PubChem CID
- 5310993
- DTXSID
DTXSID2046202- ChEMBL
CHEMBL345714- ChEBI
CHEBI:94688- UNII
- K9AY9IR2SD
- EC Number
- 256-928-3
- Nikkaji
- J10.290C
物性
構造計算による物性
- XLogP
- -1
- 極性表面積
- 75.7 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 4
- 回転可能結合数
- 1
- 重原子数
- 11
- 形式電荷
- 0
- 複雑度
- 162
実験および物理化学的性質
Drugs
Pharmaceuticals -> Antilipidemics
Pharmaceuticals -> Listed in ZINC15
物理化学的性質
- 融点
- 177 · 177-180 °C
- 沸点
- 539 · 539.0±45.0 °C(Predicted)
- 比重(密度)
- 1.44 · 1.44±0.1 g/cm3(Predicted)
- 貯蔵温度
- 2 · Inert atmosphere,2-8°C
- 溶解性
- メタノール、水 (100mM)、DMSO (100mM)、エタノール (<1mg/ml、25°C)、1M NH4OH (1mg/ml) に可溶。
- 外見
- 個体
- 酸解離定数(Pka)
- 2.8 · 2.80±0.10(Predicted)
- 色
- 黄色
- Merck
- 14 · 14,111
- InChI
- InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)
- InChIKey
- DJQOOSBJCLSSEY-UHFFFAOYSA-N
- SMILES
- C1(C(O)=O)N=CC(C)=[N+]([O-])C=1
- CAS データベース
- 51037 · 51037-30-0(CAS DataBase Reference)
- EPAの化学物質情報
- 5 · Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (51037-30-0)
化学的性質
化学的特性Yellow Solid
安全と法規制
GHS分類
GHS Classification
This chemical does not meet GHS hazard criteria for 41.7% (30 of 72) of reports.
Warning
H319 (58.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)
Aggregated GHS information provided per 72 reports by companies from 3 notifications to the ECHA C&L Inventory.
危険有害性情報
安全データ
- wgk
- 3
- rtecs
- UQ2453000
- 毒性
- LD50 orally in mice: 3500 mg/kg (Ambrogi)
- hs_code
- 2933.99.8290
- risk_code
- 36
- hazard_code
- Xi
- safety_code
- 26
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
ATC Code
C10AD06
C - Cardiovascular system
QC - Cardiovascular system
応用分野
説明Acipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.
使用Acipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.
調製方法
製造方法Synthesis of acipimox: Under cooling and stirring, 78 g of maleic anhydride was dissolved in a solution of 60 ml of chloroform, and 40 ml of 30% hydrogen peroxide was added. After 2 h, 4.8 g of 5-Methyl-2-pyrazinecarboxylic acid was added, and the temperature was kept at 0-5 °C for 2 d. The maleic acid was filtered off. Concentrate to a small volume, add ethyl acetate, and filter to obtain 1.1 g of acipimox, the melting point of which is 178-180 °C.
上流・下流製品情報
上流原料
サプライヤー50 社
関連反応
関連ノート
読み込み中…